Researchers buoyed by novel HIV drugs: will expand...[JAMA. 2007]

SearchDatabase nameforSearch term

Your browser version may not work well with NCBI's Web applications. More information here...

Display Show

All: 1

Review: 0

1: JAMA. 2007 Apr 11;297(14):1535-6. Links

Researchers buoyed by novel HIV drugs: will expand drug arsenal against resistant virus.

PMID: 17426263 [PubMed - indexed for MEDLINE]

Two new drugs for HIV infection.
Med Lett Drugs Ther. 2008 Jan 14; 50(1277):2-4.

[Med Lett Drugs Ther. 2008]
Anti-HIV agents. New drugs--hope and a degree of caution.
TreatmentUpdate. 2007 Sep-Oct; 19(6):9-10.

[TreatmentUpdate. 2007]
Anti-HIV agents. New drugs, new hope, old lessons.
TreatmentUpdate. 2007 Feb; 19(2):1-3.

[TreatmentUpdate. 2007]
ReviewNew treatment options for HIV salvage patients: an overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists.
J Infect. 2008 Jul; 57(1):1-10. Epub 2008 Jun 16.

[J Infect. 2008]
ReviewThe clinical pharmacology of antiretrovirals in development.
Expert Opin Drug Metab Toxicol. 2006 Jun; 2(3):447-58.

[Expert Opin Drug Metab Toxicol. 2006]
» See reviews... | » See all...

Combating HIV resistance - focus on darunavir.
Tremblay CL. Ther Clin Risk Manag. 2008 Aug; 4(4):759-66.

[Ther Clin Risk Manag. 2008]

Maraviroc (Selzentry® )
Maraviroc is used with other medications to treat human immunodeficiency virus (HIV) in patients with or without acquired immunodeficiency syndrome (AIDS). Maraviroc is in a class of antiviral medications called CCR5 co-...
Raltegravir (Isentress® )
Raltegravir is used in combination with other medications to treat human immunodeficiency virus (HIV) infection. Raltegravir is in a class of medications called HIV integrase strand transfer inhibitors. It works by slowi...
Source: AHFS Consumer Medication Information

Your browsing activity is empty.

Activity recording is turned off.

Display Show